Nanobiotix announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and No?l Kurdi as the Director of Investor Relations. These high level profiles will contribute to reinforce Nanobiotix’s presence in the US by strengthening its clinical development and by leveraging US investors potential to continue the growth of the Company. Dr. Mihail Obrocea joined Nanobiotix from SFJ Pharmaceuticals Group, where he held the position of Vice President of Clinical & Medical Affairs. No?l Kurdi joined Nanobiotix from the Trout Group & Trout Capital, where she served as a Senior Associate, providing strategic investor relations counsel to US based and multinational biotech companies seeking access to the US and international capital markets.